Fig 1: CD276-expression is high on SCLC primary patient samples. (A) Analysis of 79 primary patient samples showed a higher gene expression of CD276 compared to DLL3. n = 79. ****p < 0.0001 (unpaired t-test). (B) Based on the mRNA analysis of cell lines derived from tumor patient samples, CD276 is broadly expressed on all four subtypes of SCLC. CD276-expression is significantly higher than DLL3-expression in the subtypes ASCL1 and YAP1. n as shown. ***p < 0.001. ****p < 0.0001 (Two-way ANOVA). (C) CD276-expression on four different SCLC cell lines was analysed via flow cytometry and showed high expression on all. (D) IHC staining of CD276 on a TMA of 39 primary patient samples was evaluated. Exemplary pictures show low expression (left; score 1), medium expression (middle; score 2) and high expression (right; score 3). Scale bar represents 50 μm. Positive cell to negative cell ratio was calculated from tumor regions (exemplarily highlighted by square) and showed (E) high expression in 71.8% of the samples. (F) H-score was calculated by multiplying the percentage of positive cells with the score
Fig 2: Upregulation of CD276 on activated CAR-T leads to decrease in cell number and fratricide in vitro. (A) Schematic overview of the AM and AdCAR system, as well as the d CAR. (B) dCAR-T culture at day six results in lower cell numbers compared to untransduced activated T-cells and AdCAR-T. n=6. ****p<0.0001 (One-way ANOVA). Error bars indicate SD between donors. (C) After six days of co-culture with SHP-77, dCAR-T show significantly less CD276-positive cells compared to AdCAR-T. n=3. *p<0.05 (paired t-test). Error bars denote SD between donors. (D) CD276 is mainly expressed on the activated CD4-positive fraction of AdCAR-T during in vitro culture and the fractions of CD4/CD8 show comparable CD276-expression to untransduced control T-cells. n=3. ***p<0.0005 (Two-way ANOVA). (E) During expansion of CD19-CAR-T and AdCAR-T ex vivo, the initial high expression of CD276 decreases over time. n=3. Error bars denote SD between donors. (F) CD276-expression on CD19CAR-T and AdCAR-T can be re-induced by stimulation with CD19-expressing target cells every 24 h. n=4. Error bars denote SD between donors. (G) In comparison to AdCAR-T only, AdCAR-T incubated with CD276-directed Fab or full mAb show and increased fraction of dead cells (7AAD+) as well as (H) a higher frequency of activated (CD69+/CD25+) cells. n=3. Error bars denote SD between donors. *p<0.05. **p<0.01. ***p<0.0005. ****p<0.0001 (Two-way ANOVA).
Fig 3: Novel biotinylated anti-CD276 AM mediates effective tumor cell elimination through AdCAR-T in vitro. (A) AM candidates were generated of parental clones through a naïve human phage display library screening. Through affinity maturation and exclusion of candidates with potential glycosylation sites and unpaired cysteines, unique clones were identified. Lead candidates were chosen based on manufacturability and specificity. (B) EC50 of the AM candidates in the AdCAR system calculated by linear regression and (C) the respective 95% confidence limits and R2. (D) Five novel AM candidates mediate specific cell lysis of the SCLC cell line SHP-77 by AdCAR-T at different E: T ratios after 48 h of co-incubation (5 nM AM). Negative lysis is a result of the calculation and equals target cell growth and is therefore excluded. n = 3. *p < 0.05 (Two-way ANOVA). Error bars indicate SD between donors. (E) Re-challenge cycles in which AdCAR-T were repeatedly exposed to SHP-77. AdCAR-T showed target cell lysis up to three re-challenge cycles and 192 h of co-culture (2 nM AM). Error bars denote SD between donors. n = 3. *p < 0.05. **p < 0.01 (Two-way ANOVA)
Supplier Page from Thermo Fisher Scientific for Recombinant Human B7-H3 (CD276) His-tag Protein